The Government has today published more information on contingency planning for medicines supply in the event of a no deal Brexit. In response, the ABPI has highlighted the need to provide more detail, so that companies can make plans.
07 Dec 2018 Posted in
News
By
Communications
Mike Thompson, Chief Executive of the ABPI said:
“Pharmaceutical companies continue to do everything in their power to make sure that patients get access to medicines whatever the Brexit scenario. This includes duplicating processes, changing supply routes and stockpiling medicines in line with the Government’s guidance. However, we have been clear that there are things which are out of our control.
“Today’s update on potential border delays for six months in a no deal scenario is stark. Stockpiling more medicines is not the solution to this problem.
"We welcome the Secretary of State’s intention to prioritise the flow of medicines and vaccines. But with just 16 weeks until the UK leaves the EU, we need the detail.
"The Government should to take immediate action to open up alternative supply routes between the UK and Europe and tell companies so that they can make plans.”
